NK Cell Subpopulations and Receptor Expression in Recovering SARS-CoV-2 Infection

[1]  M. Alberoni,et al.  Clinical course of SARS-CoV-2 infection in patients with severe acquired brain injury and a disorder of consciousness: an observational study , 2021, Brain injury.

[2]  W. Lau,et al.  Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19 , 2021, Cell.

[3]  H. Nozad Charoudeh,et al.  The role of KIR positive NK cells in diseases and its importance in clinical intervention. , 2021, International immunopharmacology.

[4]  P. Maes,et al.  Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes , 2021, Emerging infectious diseases.

[5]  J. C. Cohen Tervaert,et al.  Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19 , 2020, Blood Advances.

[6]  T. Ohtsuka,et al.  Programmed cell death 1‐expressing CD56‐negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment , 2020, Cancer science.

[7]  F. Vély,et al.  Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19 , 2020, Cellular & Molecular Immunology.

[8]  Aaron J. Wilk,et al.  A single-cell atlas of the peripheral immune response in patients with severe COVID-19 , 2020, Nature Medicine.

[9]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[10]  R. Bruno,et al.  Unique immunological profile in patients with COVID-19 , 2020, Cellular & Molecular Immunology.

[11]  S. Eyre,et al.  Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing. , 2020, Blood advances.

[12]  Hongming Miao,et al.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.

[13]  Ke Ma,et al.  Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study , 2020, BMJ.

[14]  Z. Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[15]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[17]  M. Kikkert,et al.  Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections , 2019, Viruses.

[18]  J. Verbsky,et al.  Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome , 2019, Nature Communications.

[19]  C. Hess,et al.  CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age , 2019, Aging.

[20]  Aaron J. Wilk,et al.  Diversification of human NK cells: Lessons from deep profiling , 2018, Journal of leukocyte biology.

[21]  T. Michel,et al.  Human CD56bright NK Cells: An Update , 2016, The Journal of Immunology.

[22]  L. Lanier,et al.  Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. , 2015, Immunity.

[23]  A. Muntasell,et al.  Antibody-Mediated Response of NKG2Cbright NK Cells against Human Cytomegalovirus , 2015, The Journal of Immunology.

[24]  Sungjin Kim,et al.  Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcRγ Deficiency , 2013, The Journal of Immunology.

[25]  F. Guerini,et al.  NK cells in human disease: an evolving story. , 2012, Clinical immunology.

[26]  F. Guerini,et al.  Activating KIR/HLA complexes in classic Kaposi's Sarcoma , 2012, Infectious Agents and Cancer.

[27]  R. Maserati,et al.  KIR-HLA Genotypes in HIV-Infected Patients Lacking Immunological Recovery despite Effective Antiretroviral Therapy , 2011, PloS one.

[28]  R. Maserati,et al.  Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals. , 2011, The Journal of infectious diseases.

[29]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[30]  H. Ljunggren,et al.  Expansion of Functionally Skewed CD56-Negative NK Cells in Chronic Hepatitis C Virus Infection: Correlation with Outcome of Pegylated IFN-α and Ribavirin Treatment1 , 2009, The Journal of Immunology.

[31]  E. Wherry,et al.  Redefining Chronic Viral Infection , 2009, Cell.

[32]  E. Andrès,et al.  CD56bright natural killer (NK) cells: an important NK cell subset , 2009, Immunology.

[33]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[34]  Hendrik Streeck,et al.  Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. , 2005, Blood.

[35]  J. McCluskey,et al.  Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Fauci,et al.  Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Daucher,et al.  Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Keith Hoots,et al.  Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS , 2002, Nature Genetics.

[39]  M. Caligiuri,et al.  The biology of human natural killer-cell subsets. , 2001, Trends in immunology.

[40]  G. Trinchieri,et al.  Human natural killer cells. , 1979, Transplantation proceedings.

[41]  A. Moretta,et al.  Bridging innate NK cell functions with adaptive immunity. , 2011, Advances in experimental medicine and biology.

[42]  Derek Middleton,et al.  KIR genes. , 2005, Transplant immunology.